CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 630 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Overcoming a Cancer Nemesis? KRAS Inhibitor Shows Promise in Early Trial December 5, 2019 What Survivors Should Know When Transitioning From Cancer Care to Primary... April 4, 2023 Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... October 24, 2025 Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... May 8, 2021 Load more HOT NEWS Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... Selpercatinib Shows Promise against Lung Cancers with Alterations in RET Gene A Clinical Signal of Efficacy Observed with a Combination of Nivolumab... FDA Approves Relugolix for Advanced Prostate Cancer
